Shelter Pathogen Polymerase Chain Reaction (PCR) Screening Programs Market Report 2026

The shelter pathogen polymerase chain reaction (PCR) screening programs market size has grown strongly in recent years. It will grow from $1.1 billion in 2025 to $1.21 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to rising incidence of infectious diseases in animal shelters, increasing adoption of molecular diagnostic techniques, growing awareness of zoonotic disease risks, limited availability of rapid testing in shelters, expansion of veterinary diagnostic laboratories.

The shelter pathogen polymerase chain reaction (PCR) screening programs market size is expected to see rapid growth in the next few years. It will grow to $1.78 billion by 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for early disease detection in animal populations, growth of automated and high-throughput PCR systems, rising investment in animal health infrastructure, expansion of preventive veterinary screening programs, advancement in portable and point-of-care molecular diagnostics. Major trends in the forecast period include expansion of real-time PCR-based pathogen surveillance in animal shelters, increasing adoption of multiplex PCR testing for rapid disease detection, rising use of automated nucleic acid extraction systems in shelter diagnostics, growing integration of portable PCR devices for point-of-care screening, increasing focus on outbreak prevention through routine molecular screening programs.

The rising prevalence of infectious diseases in shelter animals is expected to propel the growth of the shelter pathogen polymerase chain reaction (PCR) screening programs market going forward. Infectious diseases in shelter animals refer to illnesses caused by harmful pathogens such as viruses and bacteria that spread quickly among dogs, cats, and other animals kept in close-contact shelter environments. The increasing prevalence of infectious diseases in shelter settings is primarily driven by rising animal intake volumes along with declining vaccination rates during the post-pandemic period, as lower immunization coverage creates larger vulnerable populations in already overcrowded facilities. The growing incidence of infectious diseases in shelter animals directly increases demand for precise pathogen identification tools such as polymerase chain reaction (PCR) screening programs, as early and accurate detection of causative agents is critical for implementing effective population-level containment and treatment strategies. For instance, in November 2023, according to the Colorado Department of Agriculture, a US-based state government agency responsible for regulating animal health and agricultural activities, there were twice as many canine infectious respiratory disease cases compared to levels typically recorded during a standard outbreak period, with similar increases simultaneously reported across at least 10 U. S. states between 2022 and 2023. Therefore, the rising prevalence of infectious diseases in shelter animals is driving the growth of the shelter pathogen polymerase chain reaction (PCR) screening programs market.

The rising pet ownership is expected to propel the growth of the shelter pathogen polymerase chain reaction (PCR) screening programs market going forward. Pet ownership refers to the practice of keeping domesticated animals, including dogs and cats, as companions within households. The growing prevalence of pet ownership is mainly driven by changing generational attitudes, especially among younger populations who increasingly consider pets as family members, resulting in higher adoption rates across households. The increasing number of pets entering homes and animal shelters strengthens the need for accurate and rapid pathogen detection tools, as a greater number of animals require health screening before adoption or placement to reduce the risk of disease transmission. For instance, in March 2025, according to the American Pet Products Association (APPA), a US-based trade organization, the total number of U. S. pet-owning households increased from 82 million in 2023 to 94 million in 2024. Therefore, rising pet ownership is driving the growth of the pathogen polymerase chain reaction (PCR) screening programs market.

Leading companies operating in the shelter pathogen polymerase chain reaction (PCR) screening programs market are concentrating on developing advanced molecular diagnostic solutions, such as rapid multiplex PCR tests, to improve pathogen detection speed, enhance diagnostic accuracy, and support timely disease management in high-risk animal populations. Rapid multiplex PCR tests refer to advanced molecular assays capable of simultaneously identifying multiple infectious pathogens from a single sample, thereby improving workflow efficiency and reducing turnaround time in shelter environments. For instance, in June 2025, Enalees launched Rhéa, a new range of veterinary rapid molecular tests developed for point-of-care applications. These tests utilize real-time PCR technology to provide fast and reliable detection of infectious diseases in companion animals, supporting early diagnosis and improved clinical decision-making, particularly in environments such as animal shelters where rapid screening and disease containment are critical.

Major companies operating in the shelter pathogen polymerase chain reaction (pcr) screening programs market are Thermo Fisher Scientific Inc, Zoetis Inc, Eurofins Scientific SE, Agilent Technologies Inc, bioMérieux SA, IDEXX Laboratories Inc, Bio-Rad Laboratories Inc, QIAGEN NV, GenScript Biotech Corporation, Randox Laboratories Ltd, Bioneer Corporation, IDvet, Creative Diagnostics, Primerdesign Ltd (Novacyt Group), GeneReach Biotechnology Corp, Ring Biotechnology Co Ltd (RINGBIO), VetFor Diagnostic Systems, Invitek Diagnostics GmbH, ViroVet NV, BioVenic, Enzo Life Sciences Inc.

North America was the largest region in the shelter pathogen polymerase chain reaction (PCR) screening programs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shelter pathogen polymerase chain reaction (PCR) screening programs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the shelter pathogen polymerase chain reaction (PCR) screening programs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The shelter pathogen polymerase chain reaction (PCR) screening programs market consists of revenues earned by entities by providing services such as sample collection and handling, pathogen surveillance and reporting, outbreak risk assessment, and infection control planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The shelter pathogen polymerase chain reaction (PCR) screening programs market also includes sales of thermal cyclers, biosafety cabinets, centrifuges, and gel electrophoresis systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.